Literature DB >> 29524073

Correction to: Eculizumab: A Review in Generalized Myasthenia Gravis.

Sohita Dhillon1.   

Abstract

The article Eculizumab: A Review in Generalized Myasthenia Gravis, written by Sohita Dhillon, was originally published Online First without open access.

Entities:  

Year:  2018        PMID: 29524073      PMCID: PMC5866275          DOI: 10.1007/s40265-018-0889-3

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


Correction to: Drugs 78(3):367–376 (2018) 10.1007/s40265-018-0875-9

The article Eculizumab: A Review in Generalized Myasthenia Gravis, written by Sohita Dhillon, was originally published Online First without open access. After publication in volume 78, issue 3, pages 367–376 Alexion Pharmaceuticals Inc. requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by Alexion Pharmaceuticals Inc. Further details may be found at http://www.medengine.com/Redeem/39FCF0602D6721C2. The article is forthwith distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.
  2 in total

1.  The Beneficial Clinical Effects of Teriflunomide in Experimental Autoimmune Myasthenia Gravis and the Investigation of the Possible Immunological Mechanisms.

Authors:  Emel Koseoglu; Neslihan Sungur; Sabahattin Muhtaroglu; Gokmen Zararsiz; Ahmet Eken
Journal:  Cell Mol Neurobiol       Date:  2022-10-11       Impact factor: 4.231

Review 2.  Exploiting protease activation for therapy.

Authors:  Chloe Bleuez; Wolfgang F Koch; Carole Urbach; Florian Hollfelder; Lutz Jermutus
Journal:  Drug Discov Today       Date:  2022-03-18       Impact factor: 8.369

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.